Linked Life Data

17297262

Source:http://linkedlifedata.com/resource/pubmed/id/17297262

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2007-2-13
pubmed:abstractText
Hypothyroidism has various cardiovascular manifestation and exhibits electrocardiographic change. The QT dispersion on surface ECG reflects regional variations in myocardial repolarization. The effect of L-thyroxine treatment on ECG parameters, such as QT dispersion, in patients with primary hypothyroidism were investigated. This study involved 18 patients (3 men, 15 women, ages: 48+/-18 yr) with primary hypothyroidism. All patients were checked with a standard 12-lead ECG before and after L-thyroxine treatment. Various ECG parameters were then measured twice. The mean L-thyroxine treatment duration was 22+/-2.7 months. The mean thyroid-stimulating hormone levels of patients before and after therapy were 40.2+/-29.8 microU/mL, 3.6+/-4.6 microU/mL (p<0.001) and free-T4 levels were 0.44+/-0.38 ng/dL, 1.51+/-0.39 ng/dL (p<0.001). After L-thyroxine treatment, QT interval (395+/-42 vs. 380+/-24 msec, p<0.05), QTc interval (434+/-32 vs. 417+/-23 msec, p<0.05), QT dispersion (45+/-23 vs. 30+/-13 msec, p=0.008), QTc dispersion (49+/-23 vs. 32+/-14 msec, p=0.005) significantly decreased. There were no significant changes in the PR and RR intervals, as well as the QRS duration. Our findings suggest that the thyroid hormone affects ventricular inhomogenicity, and that L-thyroxine replacement therapy may reduce malignant ventricular arrhythmia and sudden cardiac death in primary hypothyroidism.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/17297262-11525269, http://linkedlifedata.com/resource/pubmed/commentcorrection/17297262-11780378, http://linkedlifedata.com/resource/pubmed/commentcorrection/17297262-1423949, http://linkedlifedata.com/resource/pubmed/commentcorrection/17297262-16538077, http://linkedlifedata.com/resource/pubmed/commentcorrection/17297262-1723767, http://linkedlifedata.com/resource/pubmed/commentcorrection/17297262-2220619, http://linkedlifedata.com/resource/pubmed/commentcorrection/17297262-2929445, http://linkedlifedata.com/resource/pubmed/commentcorrection/17297262-5569633, http://linkedlifedata.com/resource/pubmed/commentcorrection/17297262-6133415, http://linkedlifedata.com/resource/pubmed/commentcorrection/17297262-8074036, http://linkedlifedata.com/resource/pubmed/commentcorrection/17297262-8831416, http://linkedlifedata.com/resource/pubmed/commentcorrection/17297262-9761386
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1011-8934
pubmed:author
pubmed:issnType
Print
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
114-6
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
The effects of L-thyroxine treatment on QT dispersion in primary hypothyroidism.
pubmed:affiliation
Department of Internal Medicine, School of Medicine, Wonkwang University, Wonkwang Medical Science Research Center, Iksan, Korea.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't